Table 2. Summary of immunophenotypic characterization of AITL by flow cytometry.

Antigen/pattern	Bone marrow (%)	Peripheral blood (%)	Lymph node (%)	Body fluid (%)
Surface CD3 (N = 97)	N = 41	N = 16	N = 31	N = 9
Complete loss	26 (63.4)	13 (81.3)	12 (38.7)	2 (22.2)
Partial loss		1 (6.3)	4 (12.9)
↓intensity	12 (29.3)	2 (12.5)	15 (48.4)	4 (44.4)
↑Intensity	2 (4.9)
TCRαβ (N = 80)	N = 39	N = 12	N = 22	N = 8
Complete loss	25 (64.1)	10 (83.3)	11 (50.0)	2 (25.0)
↓intensity	1 (2.6)	2 (16.7)	5 (22.7)
CD10 (N = 85)	N = 36	N = 14	N = 27	N = 8
CD10+	5 (13.9 %)	4 (28.6)	11 (40.7)	5 (62.5)
CD10+ (partial or subset)	13 (36.1 %)	5 (35.7)	13 (48.1)	2 (25)
CD7 (N = 86)	N = 39	N = 14	N = 24	N = 9
Complete loss	16 (41.0)	4 (28.6)	9 (37.5)	8 (88.9)
Partial loss	9 (23.1)	1 (7.1)	1 (4.2)	1 (11.1)
↓intensity	2 (5.1)		1 (4.2)
↑Intensity			1
CD4 (N = 97)	N = 41	N = 16	N = 31	N = 9
↓intensity	2 (4.9)		4 (12.9)	4 (44.4)
↑Intensity			1 (3.2)
CD52 (N = 81)	N = 38	N = 13	N = 22	N = 8
Complete loss	5 (13.2)
↓intensity			2 (9.1)
CD5 (N = 89)	N = 40	N = 15	N = 26	N = 8
Complete loss	1 (2.5)		1 (3.8)
CD2 (N = 85)	N = 40	N = 14	N = 23	N = 8
Complete loss	1 (2.5)
CD8 (N = 97)	N = 41	N = 16	N = 31	N = 9
Partial expression (CD4+/CD8+)	1 (2.4)

A subset of specimens showed more than one immunophenotypic aberrancy in one (e.g., partial loss and decreased intensity) or more antigens.